Previous Article | Next Article 
Infection and Immunity, December 2004, p. 7306-7310, Vol. 72, No. 12
0019-9567/04/$08.00+0 DOI: 10.1128/IAI.72.12.7306-7310.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Use of Translational Fusion of the MrpH Fimbrial Adhesin-Binding Domain with the Cholera Toxin A2 Domain, Coexpressed with the Cholera Toxin B Subunit, as an Intranasal Vaccine To Prevent Experimental Urinary Tract Infection by Proteus mirabilis
Xin Li,1,
Jarrod L. Erbe,2,
,
C. Virginia Lockatell,3
David E. Johnson,3
Michael G. Jobling,2
Randall K. Holmes,2 and
Harry L. T. Mobley1*
Department of Microbiology and Immunology, University of Maryland School of Medicine,1
Division of Research Affairs, Veterans Administration Hospital, Baltimore, Maryland,2
Department of Microbiology, University of Colorado Health Sciences Center, Denver, Colorado3
Received 8 June 2004/
Returned for modification 29 July 2004/
Accepted 20 August 2004
This is a follow-up to our previous study using an intranasal vaccine composed of MrpH, the tip adhesin of the MR/P fimbria, and cholera toxin to prevent urinary tract infection by Proteus mirabilis (X. Li, C. V. Lockatell, D. E. Johnson, M. C. Lane, J. W. Warren, and H. L. Mobley, Infect. Immun. 72:66-75, 2004). Here, we have expressed a cholera toxin-like chimera in which the MrpH adhesin-binding domain (residues 23 to 157) replaces the cholera toxin A1 ADP-ribosyltransferase domain. This chimera, when administered intranasally without additional adjuvant, is sufficient to induce protective immunity in mice.
* Corresponding author. Present address: Department of Microbiology and Immunology, University of Michigan Medical School, 5641 Medical Science Bldg. II, 1150 West Medical Center Dr., Ann Arbor, MI 48109. Phone: (734) 763-3531. Fax: 734-764-3562. E-mail:
hmobley{at}umich.edu.
Editor: A. D. O'Brien
X.L. and J.L.E. contributed equally to this work.
Present address: Department of Life Science, Wisconsin Lutheran College, Milwaukee, WI 53226.
Infection and Immunity, December 2004, p. 7306-7310, Vol. 72, No. 12
0019-9567/04/$08.00+0 DOI: 10.1128/IAI.72.12.7306-7310.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Alamuri, P., Eaton, K. A., Himpsl, S. D., Smith, S. N., Mobley, H. L. T.
(2009). Vaccination with Proteus Toxic Agglutinin, a Hemolysin-Independent Cytotoxin In Vivo, Protects against Proteus mirabilis Urinary Tract Infection. Infect. Immun.
77: 632-641
[Abstract]
[Full Text]
-
Nielubowicz, G. R., Smith, S. N., Mobley, H. L. T.
(2008). Outer Membrane Antigens of the Uropathogen Proteus mirabilis Recognized by the Humoral Response during Experimental Murine Urinary Tract Infection. Infect. Immun.
76: 4222-4231
[Abstract]
[Full Text]
-
Jacobsen, S. M., Stickler, D. J., Mobley, H. L. T., Shirtliff, M. E.
(2008). Complicated Catheter-Associated Urinary Tract Infections Due to Escherichia coli and Proteus mirabilis. Clin. Microbiol. Rev.
21: 26-59
[Abstract]
[Full Text]
-
Hajishengallis, G., Arce, S., Gockel, C.M., Connell, T.D., Russell, M.W.
(2005). Immunomodulation with Enterotoxins for the Generation of Secretory Immunity or Tolerance: Applications for Oral Infections. JDR
84: 1104-1116
[Abstract]
[Full Text]
-
Tinker, J. K., Erbe, J. L., Holmes, R. K.
(2005). Characterization of Fluorescent Chimeras of Cholera Toxin and Escherichia coli Heat-Labile Enterotoxins Produced by Use of the Twin Arginine Translocation System. Infect. Immun.
73: 3627-3635
[Abstract]
[Full Text]